CSL Limited (OTCMKTS:CSLLY – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $80.22 and last traded at $80.96, with a volume of 68426 shares trading hands. The stock had previously closed at $84.59.
Wall Street Analysts Forecast Growth
Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a report on Thursday, January 16th.
Get Our Latest Report on CSLLY
CSL Stock Down 4.3 %
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
- Five stocks we like better than CSL
- Insider Trades May Not Tell You What You Think
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- How to Capture the Benefits of Dividend Increases
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Trading Halts Explained
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
